+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Neurotransmitter"

Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Epilepsy - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 280 Pages
  • Global
From
Migraine - Pipeline Insight, 2025 - Product Thumbnail Image

Migraine - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Subarachnoid Hemorrhage- Pipeline Insight, 2025 - Product Thumbnail Image

Subarachnoid Hemorrhage- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Brain Hemorrhage - Pipeline Insight, 2025 - Product Thumbnail Image

Brain Hemorrhage - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 75 Pages
  • Global
From
Spinocerebellar Ataxias - Pipeline Insight, 2025 - Product Thumbnail Image

Spinocerebellar Ataxias - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
5-HT1D Agonist - Pipeline Insight, 2025 - Product Thumbnail Image

5-HT1D Agonist - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Dystonia - Pipeline Insight, 2025 - Product Thumbnail Image

Dystonia - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Tourette Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Tourette Syndrome - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Drug-Resistant Refractory Epilepsy - Pipeline Insight, 2025 - Product Thumbnail Image

Drug-Resistant Refractory Epilepsy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025 - Product Thumbnail Image

Muscarinic Acetylcholine Receptor M1 Antagonists- Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 60 Pages
  • Global
From
Gilles De La Tourette's Syndrome - Pipeline Insight, 2025 - Product Thumbnail Image

Gilles De La Tourette's Syndrome - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 40 Pages
  • Global
From
From
Epilepsy - Epidemiology Forecast - 2032 - Product Thumbnail Image

Epilepsy - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 197 Pages
  • Global
From
From
United States AUSTEDO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States AUSTEDO Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
Ingrezza Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Ingrezza Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
Parkinson's Disease - Pipeline Insight, 2025 - Product Thumbnail Image

Parkinson's Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 280 Pages
  • Global
From
Myotonic Dystrophy - Pipeline Insight, 2025 - Product Thumbnail Image

Myotonic Dystrophy - Pipeline Insight, 2025

  • Drug Pipelines
  • April 2025
  • 80 Pages
  • Global
From
Autistic Disorder- Pipeline Insight, 2025 - Product Thumbnail Image

Autistic Disorder- Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Neurotransmitter market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Neurotransmitters are chemicals that are released by neurons to send signals to other cells. These drugs are used to treat a variety of neurological disorders, including depression, anxiety, and schizophrenia. Neurotransmitter drugs work by either increasing or decreasing the amount of neurotransmitters in the brain. The Neurotransmitter market is highly competitive, with many companies offering a variety of drugs. Some of the major players in the market include Pfizer, GlaxoSmithKline, Eli Lilly, and Merck. Other companies such as Novartis, AstraZeneca, and Johnson & Johnson also have a presence in the Neurotransmitter market. Show Less Read more